|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.97 USD | +0.11% |
|
-4.20% | +5.42% |
| 02-06 | Diary - U.S. earnings week ahead | RE |
| 02-05 | Insulet Launches Omnipod® 5 and Omnipod Discover? in the Middle East to Transform Diabetes Care | CI |
| Capitalization | 27.29B 23.1B 21.17B 20.05B 37.23B 2,472B 38.93B 246B 97.4B 1,190B 102B 100B 4,284B | P/E ratio 2025 * |
33.7x | P/E ratio 2026 * | 28.6x |
|---|---|---|---|---|---|
| Enterprise value | 27.6B 23.36B 21.41B 20.28B 37.66B 2,500B 39.37B 249B 98.51B 1,204B 104B 101B 4,333B | EV / Sales 2025 * |
5.93x | EV / Sales 2026 * | 5.19x |
| Free-Float |
95.22% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: DexCom, Inc.
| 1 day | +0.11% | ||
| 1 week | -4.20% | ||
| Current month | -4.20% | ||
| 1 month | +0.11% | ||
| 3 months | +20.60% | ||
| 6 months | -8.42% | ||
| Current year | +5.42% |
| 1 week | 68.68 |  | 75.36 |
| 1 month | 65.6 | | 75.98 |
| Current year | 65.19 | | 75.98 |
| 1 year | 54.11 | | 93.25 |
| 3 years | 54.11 | | 142 |
| 5 years | 54.11 | | 164.86 |
| 10 years | 10.66 | | 164.86 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jacob Leach
CEO | Chief Executive Officer | 47 | 01/01/2026 |
Jereme Sylvain
DFI | Director of Finance/CFO | 46 | 19/03/2021 |
| Chief Tech/Sci/R&D Officer | 49 | 01/10/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Kevin Sayer
CHM | Chairman | 68 | 30/07/2018 |
Nick Augustinos
BRD | Director/Board Member | 67 | 20/11/2009 |
Jacob Leach
BRD | Director/Board Member | 47 | 01/01/2026 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -1.34% | 1.46% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.11% | -4.20% | -20.78% | -34.44% | 27.29B | |
| +1.60% | +1.40% | -13.56% | +0.07% | 193B | |
| -0.05% | -0.06% | +13.30% | +20.72% | 132B | |
| +2.01% | +0.01% | +45.96% | +132.54% | 69.89B | |
| +1.70% | +3.21% | -7.57% | -16.05% | 59.84B | |
| -1.84% | +2.22% | +36.21% | +85.77% | 56.95B | |
| +2.38% | +7.01% | - | - | 39.36B | |
| +3.42% | -3.98% | +11.85% | +17.48% | 24.75B | |
| -1.93% | -5.52% | -16.56% | -49.60% | 20.45B | |
| +0.69% | +1.36% | -28.12% | +6.07% | 19.21B | |
| Average | +0.81% | -0.14% | +2.30% | +18.06% | 64.24B | |
| Weighted average by Cap. | +0.93% | +0.76% | +4.66% | +24.09% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 4.66B 3.94B 3.61B 3.42B 6.35B 422B 6.64B 41.97B 16.62B 203B 17.46B 17.1B 731B | 5.23B 4.43B 4.06B 3.84B 7.14B 474B 7.46B 47.16B 18.67B 228B 19.62B 19.21B 821B |
| Net income | 831M 704M 645M 611M 1.13B 75.3B 1.19B 7.49B 2.97B 36.25B 3.12B 3.05B 130B | 989M 837M 767M 727M 1.35B 89.58B 1.41B 8.91B 3.53B 43.12B 3.71B 3.63B 155B |
| Net Debt | 310M 263M 241M 228M 423M 28.11B 443M 2.8B 1.11B 13.53B 1.16B 1.14B 48.71B | -146M -123M -113M -107M -199M -13.21B -208M -1.31B -521M -6.36B -547M -536M -22.9B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/02/26 | 69.97 $ | +0.11% | 3,659,937 |
| 05/02/26 | 69.89 $ | -1.31% | 5,571,968 |
| 04/02/26 | 70.82 $ | -1.13% | 7,051,273 |
| 03/02/26 | 71.63 $ | -1.24% | 5,026,743 |
| 02/02/26 | 72.53 $ | -0.70% | 3,274,347 |
Delayed Quote Nasdaq, February 07, 2026 at 12:00 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DXCM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition